

Ref. No: 021120422
From: Commercial
Date: 12/04/22
Subject: Diabetic retinopathy patients

REQUEST & RESPONSE

1. How many current diabetic retinopathy (including DMO) patients do you have?*

1593 according to MediSight system (2017-2022)

2. How many diabetic retinopathy (including DMO) patients do you have that are currently being monitored and held at "wait and see" but not yet progressed to needing any treatments (injections/laser/implant)?*

All patients on active monitoring/treatment (figure above), we do not have a database for "wait and see".

3. How many diabetic retinopathy (including DMO) patients do you have that have received treatment (injections/laser/implants) in the year April 2019-March 2020 inclusive (i.e. pre COVID-19)?*

According to MediSight:

Patients	Number	Percentage
Diabetic Patients	416	
With an Assessment	290	69.71%
With a Consultation	112	26.92%
With an Operation	322	77.40%
With an anti-VEGF IVI	176	42.31%
With a steroid IVI	25	6.01%
With a retinal laser	<5	0.48%
With a cyclodiode laser	0	0.00%

Please note <5 has been added where the number of patients is 5 or less, this

information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.

It would take too long to gather data regarding laser treatment for diabetic patients only.

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.

4. How many diabetic retinopathy (including DMO) patients do you have that have received treatment (injections/laser/implants) in the year April 2020-March 2021 inclusive (i.e. during COVID-19)?*

According to MediSight:

Patients	Number	Percentage
Diabetic Patients	424	
With an Assessment	346	81.60%
With a Consultation	179	42.22%
With an Operation	309	72.88%
With an anti-VEGF IVI	203	47.88%
With a steroid IVI	31	7.31%
With a retinal laser	<5	0.47%
With a cyclodiode laser	0	0.00%

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.

It would take too long to gather data regarding laser treatment for diabetic patients only.

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a

request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.

5. How many injections (Avastin/bevacizumab, Eylea/aflibercept, Lucentis/ranibizumab) have been used for diabetic retinopathy (including DMO) patients in the year April 2019-March 2020 inclusive (i.e. pre COVID-19)? Please break down by treatment.*

According to MediSight:

Eyelea – 104

Lucentis – 236

Ozurdex – 10 (no data for Avastin)

6. How many injections (Avastin/bevacizumab, Eylea/aflibercept, Lucentis/ranibizumab) have been used for diabetic retinopathy (including DMO) patients in the year April 2020-March 2021 inclusive (i.e. pre COVID-19)? Please break down by treatment.*

*Please break down by hospital within your trust

According to MediSight:

Eyelea – 132

Lucentis – 276

Ozurdex – 17 (no data for Avastin)

Dexamethasone – 2 (no data for Avastin)